Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1963
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 4
1964 2
1965 2
1966 2
1969 2
1970 1
1971 1
1972 1
1973 1
1974 1
1976 4
1977 1
1980 2
1985 1
1987 2
1988 1
1989 1
1990 1
1991 2
1993 1
1994 5
1995 5
1996 1
1998 4
1999 3
2000 2
2001 2
2002 4
2003 7
2004 2
2005 5
2006 4
2007 6
2008 7
2009 2
2010 5
2011 6
2012 3
2013 8
2014 8
2015 3
2016 7
2017 12
2018 8
2019 1
2020 10
2021 9
2022 6
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
[Mucopolysaccharidosis: clinical features, diagnosis and management].
Suarez-Guerrero JL, Gómez Higuera PJ, Arias Flórez JS, Contreras-García GA. Suarez-Guerrero JL, et al. Rev Chil Pediatr. 2016 Jul-Aug;87(4):295-304. doi: 10.1016/j.rchipe.2015.10.004. Epub 2015 Nov 21. Rev Chil Pediatr. 2016. PMID: 26613630 Free article. Review. Spanish.
Their identification is essential to initiate early treatment, taking into account that multidisciplinary management and enzyme replacement therapy is available for MPS I (Hurler syndrome), MPS II (Hunter syndrome), MPS IV (Morquio syndrome), and MPS V …
Their identification is essential to initiate early treatment, taking into account that multidisciplinary management and enzyme replacement …
Mucopolysaccharidosis: A broad review.
Nagpal R, Goyal RB, Priyadarshini K, Kashyap S, Sharma M, Sinha R, Sharma N. Nagpal R, et al. Indian J Ophthalmol. 2022 Jul;70(7):2249-2261. doi: 10.4103/ijo.IJO_425_22. Indian J Ophthalmol. 2022. PMID: 35791104 Free PMC article. Review.
Mucopolysaccharidosis III: Molecular basis and treatment.
Spahiu L, Behluli E, Peterlin B, Nefic H, Hadziselimovic R, Liehr T, Temaj G. Spahiu L, et al. Pediatr Endocrinol Diabetes Metab. 2021;27(3):201-208. doi: 10.5114/pedm.2021.109270. Pediatr Endocrinol Diabetes Metab. 2021. PMID: 34743503 Free PMC article. Review.
Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.
D'Avanzo F, Rigon L, Zanetti A, Tomanin R. D'Avanzo F, et al. Int J Mol Sci. 2020 Feb 13;21(4):1258. doi: 10.3390/ijms21041258. Int J Mol Sci. 2020. PMID: 32070051 Free PMC article. Review.
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome, although at first neglected for a few decades and afterwards mistaken for a long time for …
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles Hunter in 1917. Since then, about one hund …
Mucopolysaccharidoses and mucolipidoses.
Wraith JE. Wraith JE. Handb Clin Neurol. 2013;113:1723-9. doi: 10.1016/B978-0-444-59565-2.00042-3. Handb Clin Neurol. 2013. PMID: 23622395 Review.
MPS and ML are transmitted in an autosomal recessive manner, except for the X-linked MPS II (Hunter syndrome). Diagnosis is initially by detecting partially degraded GAG or oligosaccharide in urine and confirmed by specific enzyme assays in serum, leukocytes, or skin fibro …
MPS and ML are transmitted in an autosomal recessive manner, except for the X-linked MPS II (Hunter syndrome). Diagnosis is initially …
Mucopolysaccharidosis type I.
Wraith JE, Jones S. Wraith JE, et al. Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:102-6. Pediatr Endocrinol Rev. 2014. PMID: 25345091 Review.
Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of the lysosomal hydrolase a-L-Iduronidase leading to accumulation of the GAGs, dermatan sulfate, and heparan sulphate, The disease spectrum includes a disorder with severe involvement and CNS disease Hurler di …
Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of the lysosomal hydrolase a-L-Iduronidase leading to accumulation of the GAG …
Laronidase.
[No authors listed] [No authors listed] BioDrugs. 2002;16(4):316-8. doi: 10.2165/00063030-200216040-00009. BioDrugs. 2002. PMID: 12196045 Review.
BioMarin Pharmaceutical is developing laronidase, recombinant alpha-L-iduronidase enzyme replacement therapy for the treatment of mucopolysaccharidosis I (MPS-I) [the most severe form of this is called Hurler syndrome]. The company has received US and …
BioMarin Pharmaceutical is developing laronidase, recombinant alpha-L-iduronidase enzyme replacement therapy for the treatment of mucopol
Therapy for the mucopolysaccharidoses.
Valayannopoulos V, Wijburg FA. Valayannopoulos V, et al. Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v49-59. doi: 10.1093/rheumatology/ker396. Rheumatology (Oxford). 2011. PMID: 22210671 Review.
Enzyme replacement therapy (ERT) is now available for MPS I (Hurler, Hurler-Scheie and Scheie syndromes) (laronidase), MPS II (Hunter syndrome) (idursulfase) and MPS VI Maroteaux-Lamy (galsulfase), and is in development for MPS IV (Morquio syndrome) an …
Enzyme replacement therapy (ERT) is now available for MPS I (Hurler, Hurler-Scheie and Scheie syndromes) (laronidase), MPS II …
Cutaneous Manifestations of Mucopolysaccharidoses.
Tran MC, Lam JM. Tran MC, et al. Pediatr Dermatol. 2016 Nov;33(6):594-601. doi: 10.1111/pde.12971. Epub 2016 Sep 7. Pediatr Dermatol. 2016. PMID: 27601403 Review.
More specific skin findings include ivory-colored "pebbly" papules found in Hunter syndrome and extensive dermal melanocytosis found in Hurler and Hunter syndromes. Early diagnosis of MPS disorders is extremely important to minimize the progression of the disease an …
More specific skin findings include ivory-colored "pebbly" papules found in Hunter syndrome and extensive dermal melanocytosis found …
170 results